Serving the Society Since 1986
高级搜索
Volume 39 Issue 5
October 2024

    . doi: 10.1016/j.virs.2024.08.003
    Citation: Kangyin Li, Qi Liu, Yan Wu, Bihao Wu, Shaohong Chen, Xinghai Zhang, Xiaoying Jia, Rui Gong, Yucai Peng, Huajun Zhang, Sandra Chiu. A bivalent Delta/BA.5 mRNA vaccine elicits broad immune responses against various lineages of SARS-CoV-2 including JN.1 .VIROLOGICA SINICA, 2024, 39(5) : 833-835.  http://dx.doi.org/10.1016/j.virs.2024.08.003
    shu

    Delta/BA.5二价mRNA疫苗可诱导产生对包括JN.1在内的多种SARS-CoV-2变异株的广谱免疫反应

    cstr: 32224.14.j.virs.2024.08.003

    • a. 中国科学院武汉病毒研究所;

    • b. 中国科学技术大学;

    • c. 珠海丽凡达生物技术有限公司

    • 新冠病毒对全球公共健康造成了持续性威胁，已上市多种疫苗，并在预防感染、特别是重症和死亡取得了巨大成功。然而，随着新变种的不断出现，已出现突破性感染，有必要开发广谱疫苗。二价或多价疫苗是一种广谱疫苗开发策略。在本文中，我们研究了Delta/BA.5二价疫苗在K18-hACE2小鼠和仓鼠体内对Delta和BA.5病毒的有效性，结果表明Delta/BA.5疫苗免疫后可产生高水平中和抗体，并使动物免受Delta和BA.5病毒的感染；此外，动物免疫血清对其它多种突变体的活病毒或假病毒（如WIV04、BA.2、BF.7、CH1.1、BQ.1.1、XBB.1.5、XBB.1.9、EG.5和JN.1）均有中和活性，表明Delta/BA.5二价mRNA疫苗具有广谱潜力，为未来的广谱疫苗设计提供了有用信息。

    A bivalent Delta/BA.5 mRNA vaccine elicits broad immune responses against various lineages of SARS-CoV-2 including JN.1

    • a. Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430062, China;

    • b. University of Chinese Academy of Sciences, Beijing, 100049, China;

    • c. Liverna Therapeutics Inc., Zhuhai, 519000, China;

    • d. Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;

    • e. Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;

    • f. Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei, 230027, China

    • Highlights
      1. A bivalent Delta/BA.5 mRNA vaccine provides protection against BA.5 in K18-ACE2 mice.
      2. The vaccine protects hamsters from both Delta and BA.5 infections.
      3. The animal immune sera neutralizes various lineages of variants including JN.1.
    • 加载中

      1. Chalkias, S., Eder, F., Essink, B., Khetan, S., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. et al., 2022. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat. Med. 28, 2388-2397.

      2. Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G. et al., 2022. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 399, 924-944.

      3. Li J, Liu Q, Liu J, Fang Z, Luo L, Li S, Lei Y, Li Z, Jin J, Xie R, Peng Y., 2022. Development of bivalent mRNA vaccines against SARS-CoV-2 variants. Vaccines (Basel). 10, 1807.

      4. Roemer, C., Sheward, D. J., Hisner, R., Gueli, F., Sakaguchi, H., Frohberg, N., Schoenmakers, J., Sato, K., O'Toole, A., Rambaut, A. et al., 2023. SARS-CoV-2 evolution in the Omicron era. Nat Microbiol. 8, 1952-1959.

      5. Shuai, H., Chan, J. F., Hu, B., Chai, Y., Yuen, T. T., Yin, F., Huang, X., Yoon, C., Hu, J. C., Liu, H. et al., 2022. Attenuated replication and pathogenicity of SARS-CoV-2 b.1.1.529 Omicron. Nature. 603, 693-699.

      6. Ssentongo, P., Ssentongo, A. E., Voleti, N., Groff, D., Sun, A., Ba, D. M., Nunez, J., Parent, L. J., Chinchilli, V. M., Paules, C. I., 2022. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 22, 439.

      7. Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney, K., Makatini, Z., Moyo, S., Amoako, D. G. et al., 2022. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat. Med. 28, 1785-1790.

      8. Ukwishaka, J., Ndayishimiye, Y., Destine, E., Danwang, C., Kirakoya-Samadoulougou, F., 2023. Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis. BMC Public Health. 23, 778.

      9. Uraki, R., Kiso, M., Iwatsuki-Horimoto, K., Yamayoshi, S., Ito, M., Chiba, S., Sakai-Tagawa, Y., Imai, M., Kashima, Y., Koga, M. et al., 2023. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep. 42, 113580.

      10. Wu, Y., Shen, Y., Wu, N., Zhang, X., Chen, S., Yang, C., Zhou, J., Wu, Y., Chen, D., Wang, L. et al., 2022. Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates. Cell Res. 32, 949-952.

      11. Zhang, X., Chen, S., Cao, Z., Yao, Y., Yu, J., Zhou, J., Gao, G., He, P., Dong, Z., Zhong, J., et al., 2022. Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters. Virol. Sin. 37, 796-803.

    • 加载中

    • Electronic Supplementary Material

      10.1016j.virs.2024.08.003-ESM.docx

    Figures(1)

    PDF

    Article Metrics

    Article views(512) PDF downloads(14) Cited by(0)

    Related
    Proportional views
      通讯作者: 陈斌, bchen63@163.com
      • 1. 

        沈阳化工大学材料科学与工程学院 沈阳 110142

      1. 本站搜索
      2. 百度学术搜索
      3. 万方数据库搜索
      4. CNKI搜索

      A bivalent Delta/BA.5 mRNA vaccine elicits broad immune responses against various lineages of SARS-CoV-2 including JN.1

        Corresponding author: Yucai Peng, pengyucai@live-rna.com
        Corresponding author: Huajun Zhang, hjzhang@wh.iov.cn
        Corresponding author: Sandra Chiu, qiux@ustc.edu.cn
      • a. Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430062, China;
      • b. University of Chinese Academy of Sciences, Beijing, 100049, China;
      • c. Liverna Therapeutics Inc., Zhuhai, 519000, China;
      • d. Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;
      • e. Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;
      • f. Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei, 230027, China
      • Received Date: 25 October 2023
      • Accepted Date: 06 August 2024

      Abstract: Highlights
      1. A bivalent Delta/BA.5 mRNA vaccine provides protection against BA.5 in K18-ACE2 mice.
      2. The vaccine protects hamsters from both Delta and BA.5 infections.
      3. The animal immune sera neutralizes various lineages of variants including JN.1.

        HTML

      Figure (1)  Reference (11) Relative (20)

      目录

      鄂ICP备05001977号

         

      鄂公网安备 42010602003674号

      Copyright © 2019 Virologica Sinica. All rights reserved

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return